Bjork Elisabeth reported option exercise involving 17,500 derivative units of Pharvaris N.V. at $0.00 for $0 on Sep 17, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Sep 21, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
17,500Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Sep 17, 2026Option exercise
Filed
Sep 21, 2026, 3:20 PM ET4-day reporting delay
Accession
0001193125-26-396584Code M · Transaction 226498
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 17, 2026Option exercise35,000$14.39$503,650Trade 226494
Sep 17, 2026Option exercise17,500$18.14$317,450Trade 226495
Sep 17, 2026Option exercise35,000$0.00$0Trade 226497
Sep 17, 2026Sell52,500$37.89−$1,989,408.75Trade 226496
5 transaction rows in this filing. Joint filers share the same rows.

PHVS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PHVS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +0.2%1w ago +4.1%1d ago +4.2%
Returns since7d −11%30d −14%90d180d1y

Footnotes in full

F1: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.62 to $38.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F2: 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. F3: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.